PMID- 32140533
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220413
IS  - 2352-5789 (Print)
IS  - 2352-5789 (Electronic)
IS  - 2352-5789 (Linking)
VI  - 32
DP  - 2020 May
TI  - Selection of HER2/NEU negative tumor cells as a mechanism of resistance to 
      trastuzumab in uterine serous carcinoma.
PG  - 100554
LID - 10.1016/j.gore.2020.100554 [doi]
LID - 100554
AB  - BACKGROUND: Uterine serous carcinoma (USC) is an aggressive variant of 
      endometrial cancer overexpressing HER2/neu in about 30% of cases. Trastuzumab, a 
      humanized monoclonal antibody targeting Her2/Neu, in combination with 
      carboplatin/paclitaxel, is considered the preferred regimen for the treatment of 
      advanced or recurrent HER2/Neu+ USC per NCCN guidelines. CASE: We describe two 
      USC patients with overexpression of HER2/neu at 2+/3+ level by 
      immunohistochemistry and c-erbB2 gene amplification by fluorescence in situ 
      hybridization (FISH) assay that, after an initial clinical response to 
      trastuzumab, developed resistance/progression. Post-treatment biopsy (collected 
      at the time of clinical progression on trastuzumab) demonstrated loss of HER2/neu 
      overexpression in the recurrent/progressing tumor cells in both patients. 
      CONCLUSION: Selection of HER2/NEU negative tumor cells may represent a major 
      mechanism of resistance to trastuzumab in USC patients.
CI  - (c) 2020 The Author(s).
FAU - Pelligra, Silvia
AU  - Pelligra S
AD  - Department of Obstetrics, Gynecology, and Reproductive Sciences, New Haven, CT 
      06520, USA.
FAU - Buza, Natalia
AU  - Buza N
AD  - Department of Pathology, Yale University School of Medicine, New Haven, CT 06520, 
      USA.
FAU - Hui, Pei
AU  - Hui P
AD  - Department of Pathology, Yale University School of Medicine, New Haven, CT 06520, 
      USA.
FAU - Bellone, Stefania
AU  - Bellone S
AD  - Department of Obstetrics, Gynecology, and Reproductive Sciences, New Haven, CT 
      06520, USA.
FAU - Zeybek, Burak
AU  - Zeybek B
AD  - Department of Obstetrics, Gynecology, and Reproductive Sciences, New Haven, CT 
      06520, USA.
FAU - Ratner, Elena
AU  - Ratner E
AD  - Department of Obstetrics, Gynecology, and Reproductive Sciences, New Haven, CT 
      06520, USA.
FAU - Schwartz, Peter E
AU  - Schwartz PE
AD  - Department of Obstetrics, Gynecology, and Reproductive Sciences, New Haven, CT 
      06520, USA.
FAU - Scambia, Giovanni
AU  - Scambia G
AD  - Division of Gynecologic Oncology, Fondazione Policlinico Universitario A. Gemelli 
      IRCCS, Rome, Italy.
FAU - Santin, Alessandro D
AU  - Santin AD
AD  - Department of Obstetrics, Gynecology, and Reproductive Sciences, New Haven, CT 
      06520, USA.
LA  - eng
GR  - U01 CA176067/CA/NCI NIH HHS/United States
GR  - UL1 TR001863/TR/NCATS NIH HHS/United States
PT  - Case Reports
DEP - 20200225
PL  - Netherlands
TA  - Gynecol Oncol Rep
JT  - Gynecologic oncology reports
JID - 101652231
EIN - Gynecol Oncol Rep. 2021 Jan 18;35:100703. PMID: 33614877
PMC - PMC7049633
OTO - NOTNLM
OT  - HER2/neu
OT  - Recurrent
OT  - Trastuzumab
OT  - Treatment-resistant
OT  - Uterine serous carcinoma
EDAT- 2020/03/07 06:00
MHDA- 2020/03/07 06:01
PMCR- 2020/02/25
CRDT- 2020/03/07 06:00
PHST- 2020/01/06 00:00 [received]
PHST- 2020/02/18 00:00 [revised]
PHST- 2020/02/23 00:00 [accepted]
PHST- 2020/03/07 06:00 [entrez]
PHST- 2020/03/07 06:00 [pubmed]
PHST- 2020/03/07 06:01 [medline]
PHST- 2020/02/25 00:00 [pmc-release]
AID - S2352-5789(20)30020-5 [pii]
AID - 100554 [pii]
AID - 10.1016/j.gore.2020.100554 [doi]
PST - epublish
SO  - Gynecol Oncol Rep. 2020 Feb 25;32:100554. doi: 10.1016/j.gore.2020.100554. 
      eCollection 2020 May.